Leqvio Launch Will Be Fundamental To Success Of New Novartis
Outcomes Data Key In EU, Not in US
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.
You may also be interested in...
While the Phase IIb SOLANO trial of ION449 met its primary endpoint, AstraZeneca had set a high bar of 70% LDL cholesterol reduction for competitiveness that the study did not hit.
The twice-yearly cholesterol injectable approved in Europe 18 months ago is still not making any commercial headway but Novartis's CEO Vas Narasimhan has stressed that the groundwork for access to and education about Leqvio is being firmly laid.
The CEO and head of pharma at Novartis have both cautioned against expectations of a lucrative launch for Leqvio, saying that a completely new approach to treating cholesterol lowering with a vaccine-like approach of administration twice a year will take time to get established in healthcare systems.